Evidence mapPaperPMID 42438341Full record

ArticleJournal of inherited metabolic disease2026

NAXD Deficiency: Heterogeneous Phenotypes and Positive Response to Niacin Treatment.

Najmesadat Seyedkatouli, Liana N Semcesen, Lucia Gallucci, Tim Sikora, Jean-François Conrotte, Mei R M Du, Marat Kasakin, Gezime Seferi, Licia Corona, Martin Jakubec and 24 more

Abstract readCase Reports
In one paragraph

Article in Journal of inherited metabolic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Najmesadat SeyedkatouliEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Liana N SemcesenDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, the University of Melbourne, Parkville, Victoria, Australia.
Lucia GallucciEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Tim SikoraMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Jean-François ConrotteEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Mei R M DuMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Marat KasakinEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Gezime SeferiEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Licia CoronaEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Martin JakubecEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Brunda NijagalMetabolomics Australia, Bio21 Institute, the University of Melbourne, Melbourne, Victoria, Australia.
Sajel LalaDivision of Clinical Genetics, Nickelaus Children's Health System, Coral Gables, Florida, USA.
Rebecca D GanetzkyMitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania, USA.
Ana Maria Rodriguez BarretoDivision of Clinical Genetics, Nickelaus Children's Health System, Coral Gables, Florida, USA.
Marina SzlagoHospital de Niños Dr. Ricardo Gutiérrez, City of Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-8758-0762
Melanie WongThe Children's Hospital at Westmead, Westmead, Australia.
Margit ShahThe Children's Hospital at Westmead, Westmead, Australia.
James NurseUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Nicola FouldsUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Shankar SadagopanUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Ha Nguyen ThuCenter for Endocrinology, Metabolism, Genetics/Genomics and Molecular Therapy, Vietnam National Children's Hospital, Vietnam.
Dung Vu ChiCenter for Endocrinology, Metabolism, Genetics/Genomics and Molecular Therapy, Vietnam National Children's Hospital, Vietnam.ORCID https://orcid.org/0009-0007-0418-2613
Khanh Nguyen NgocCenter for Endocrinology, Metabolism, Genetics/Genomics and Molecular Therapy, Vietnam National Children's Hospital, Vietnam.
Michelle G de SilvaMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Mirana RamialisonMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Fernando RosselloMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
MitoMDT Diagnostic Network for Genomics and Omics
David R ThorburnMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0002-7725-9470
Matthew LynchNeurosciences Unit, Queensland Children's Hospital, Brisbane, Australia.
Pauline McGrathNeurosciences Unit, Queensland Children's Hospital, Brisbane, Australia.
David A StroudDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, the University of Melbourne, Parkville, Victoria, Australia.
John ChristodoulouMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0002-8431-0641
Carole L LinsterEnzymology and Metabolism Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0000-0001-7143-0719
Nicole J Van BergenMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0002-6768-3665

Funding

ACTIVE PRIDE19/14063202Australian Medical Research Future Fund (MRFF); Genomics Health Futures Mission 2007959Australian Medical Research Future Fund (MRFF); Genomics Health Futures Mission 2008820Australian Medical Research Future Fund (MRFF); Genomics Health Futures Mission 2016030Australian Medical Research Future Fund (MRFF); Genomics Health Futures Mission MRF2007959INTER European Joint Programme on Rare Diseases (EJP RD) grant INTER/EJPRD22/17557557/GENOMITLuxembourg National Research Fund (Fonds National de la Recherche - FNR) C22/BM/17198760/NAXDivoMito Foundation G189Mito Foundation G202Mito Foundation S021National Health and Medical Research Council 2009982National Health and Medical Research Council GNT1113531National Health and Medical Research Council GNT1155244National Health and Medical Research Council GNT2009732Royal Children's Hospital FoundationVictorian Government's Operational Infrastructure Support ProgramVictorian Health and Medical Research Workforce Project, The Victorian Government, The Victorian Department of Jobs, Precincts and Regions, AAMRI and VESKI Victorian Near-miss Award Pilot
6 · The paper itself

Abstract

Early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-2 (PEBEL2) is a rare autosomal recessive neurometabolic disorder caused by pathogenic variants in NAXD, in which febrile illness or infection triggers rapid clinical deterioration. We describe nine new cases that expand the clinical and molecular spectrum. Four children showed the typical presentation of severe neurological decline following fever or illness and carried variants affecting the enzyme domain. Four cases presented with illness-triggered cardiac dysfunction associated with variants in the mitochondrial targeting sequence. One case showed severe prenatal neurodegeneration resulting in stillbirth. In two patients, disease onset followed COVID-19 infection. Functional analysis of five missense variants demonstrated impaired NAXD protein solubility, reduced NADHX dehydratase activity and/or decreased thermostability. Patient fibroblasts confirmed accumulation of damaged cofactors (S-, R- and cyclic NADHX) and reduced NAXD protein levels. Comparative proteomic analysis revealed distinct molecular profiles in atypical cardiac and prenatal cases compared with typical neurological presentations. Four patients received high-dose niacin (vitamin B3) and survived repeated febrile episodes. These findings support early recognition and suggest that niacin therapy may improve outcomes across the clinical spectrum of PEBEL2.

Indexed as

LeukoencephalopathiesNiacinChildFemaleHumansMalePhenotypeNiacinmitochondriaNAXDneurodegenerationniacinpaediatricPEBEL2

Identifiers

PMID42438341
PMCPMC13358410

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.